Sandimmun/Sandimmun Neoral Indications/Uses

Transplantation: Organ transplantation: Prevention of rejection of kidney, liver, heart, combined heart-lung, lung and pancreas allografts.
Treatment of transplant rejection in patients previously treated with other immunosuppressive agents.
Because of the risk of anaphylaxis (see Precautions), Sandimmun should only be given to patients as an i.v. infusion when oral ingestion is not feasible (e.g. in the immediate post-operative period) or where gastrointestinal absorption is impaired. Such patients should be switched to oral therapy with Sandimmun Neoral as soon as possible.
Bone marrow transplantation: Prevention of graft rejection following bone marrow transplantation.
Prevention and treatment of graft-versus-host disease (GVHD).
Sandimmun Neoral: Non-transplantation indications: Endogenous uveitis: Active sight-threatening intermediate or posterior uveitis of non-infectious aetiology in which alternative therapy has proved ineffective or inappropriate.
Uveitis in Behcet's disease, with recurrent inflammatory attacks involving the retina, in patients with normal renal function who are 7 to 70 years of age.
Psoriasis: Treatment of severe cases of psoriasis in which alternative therapies are ineffective or inappropriate.
Atopic dermatitis: Treatment of severe cases of atopic dermatitis in which alternative therapies are ineffective or inappropriate.
Rheumatoid arthritis: Treatment of severe cases of rheumatoid arthritis in which standard basic therapies are ineffective or inappropriate.
Nephrotic syndrome: Idiopathic steroid-dependent or steroid-resistant nephrotic syndrome (biopsy shows minimal-change disease [MCD] or focal segmental glomerulosclerosis [FSGS] in most cases) in adults or children which has failed to respond to conventional cytostatic therapy, but only if renal function indices are at least 50% below normal values.
Induction or maintenance of remission: Maintenance of steroid-induced remission, in order to enable corticosteroids to be withdrawn.